Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 66

1.

Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.

Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A; Pasireotide C2402 Study Group.

Lancet Diabetes Endocrinol. 2014 Nov;2(11):875-84. doi: 10.1016/S2213-8587(14)70169-X. Epub 2014 Sep 24.

PMID:
25260838
[PubMed - in process]
2.

Epididymal adrenal rest tissue in a patient with congenital adrenal hyperplasia.

Bonne L, Bex M, Oyen R, Claus F.

JBR-BTR. 2014 May-Jun;97(3):193-4. No abstract available.

PMID:
25223140
[PubMed - indexed for MEDLINE]
3.

Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.

Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Sheppard M; Pasireotide C2305 Study Group.

J Clin Endocrinol Metab. 2014 Mar;99(3):791-9. doi: 10.1210/jc.2013-2480. Epub 2014 Jan 13.

PMID:
24423324
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Giant prolactinomas in women.

Delgrange E, Raverot G, Bex M, Burman P, Decoudier B, Devuyst F, Feldt-Rasmussen U, Andersen M, Maiter D.

Eur J Endocrinol. 2013 Nov 22;170(1):31-8. doi: 10.1530/EJE-13-0503. Print 2014 Jan. Review.

PMID:
24088550
[PubMed - indexed for MEDLINE]
Free Article
5.

Integrated multidisciplinary care in Parkinson's disease: a non-randomised, controlled trial (IMPACT).

van der Marck MA, Munneke M, Mulleners W, Hoogerwaard EM, Borm GF, Overeem S, Bloem BR; IMPACT study group.

Lancet Neurol. 2013 Oct;12(10):947-56. doi: 10.1016/S1474-4422(13)70196-0. Epub 2013 Aug 27.

PMID:
23988337
[PubMed - indexed for MEDLINE]
6.

In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18, but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions.

Mbunwe E, Van der Auwera BJ, Weets I, Van Crombrugge P, Crenier L, Coeckelberghs M, Seret N, Decochez K, Vandemeulebroucke E, Gillard P, Keymeulen B, van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers DG, Gorus FK; Belgian Diabetes Registry.

Diabetologia. 2013 Sep;56(9):1964-70. doi: 10.1007/s00125-013-2951-8. Epub 2013 May 28.

PMID:
23712485
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients.

Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P, Maiter D.

Pituitary. 2014 Feb;17(1):81-9. doi: 10.1007/s11102-013-0471-7.

PMID:
23446424
[PubMed - indexed for MEDLINE]
8.

HLA-A*24 is an independent predictor of 5-year progression to diabetes in autoantibody-positive first-degree relatives of type 1 diabetic patients.

Mbunwe E, Van der Auwera BJ, Vermeulen I, Demeester S, Van Dalem A, Balti EV, Van Aken S, Derdelinckx L, Dorchy H, De Schepper J, van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers D, Weets I, Gorus FK; Belgian Diabetes Registry.

Diabetes. 2013 Apr;62(4):1345-50. doi: 10.2337/db12-0747. Epub 2012 Nov 16.

PMID:
23160529
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly.

Verhelst J, Velkeniers B, Maiter D, Haentjens P, T'Sjoen G, Rietzschel E, Corvilain B, Abrams P, Nobels F, Abs R, Bex M.

Eur J Endocrinol. 2013 Jan 17;168(2):177-84. doi: 10.1530/EJE-12-0753. Print 2013 Feb.

PMID:
23132698
[PubMed - indexed for MEDLINE]
Free Article
10.

Medullary thyroid cancer: prognostic factors for survival and recurrence, recommendations for the extent of lymph node dissection and for surgical therapy in recurrent disease.

Pilaete K, Delaere P, Decallonne B, Bex M, Hauben E, Nuyts S, Clement P, Hermans R, Vander Poorten V.

B-ENT. 2012;8(2):113-21.

PMID:
22896930
[PubMed - indexed for MEDLINE]
11.

Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas.

Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Pérez L, King EE, Toledo RA, Ercolino T, Rapizzi E, Ricketts CJ, Mori L, Giacchè M, Mendola A, Taschin E, Boaretto F, Loli P, Iacobone M, Rossi GP, Biondi B, Lima-Junior JV, Kater CE, Bex M, Vikkula M, Grossman AB, Gruber SB, Barontini M, Persu A, Castellano M, Toledo SP, Maher ER, Mannelli M, Opocher G, Robledo M, Dahia PL.

JAMA. 2010 Dec 15;304(23):2611-9. doi: 10.1001/jama.2010.1830.

PMID:
21156949
[PubMed - indexed for MEDLINE]
12.

A homozygous inactivating calcium-sensing receptor mutation, Pro339Thr, is associated with isolated primary hyperparathyroidism: correlation between location of mutations and severity of hypercalcaemia.

Hannan FM, Nesbit MA, Christie PT, Lissens W, Van der Schueren B, Bex M, Bouillon R, Thakker RV.

Clin Endocrinol (Oxf). 2010 Dec;73(6):715-22. doi: 10.1111/j.1365-2265.2010.03870.x.

PMID:
20846291
[PubMed - indexed for MEDLINE]
13.

Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients.

Vandemeulebroucke E, Keymeulen B, Decochez K, Weets I, De Block C, Féry F, Van de Velde U, Vermeulen I, De Pauw P, Mathieu C, Pipeleers DG, Gorus FK; Belgian Diabetes Registry.

Diabetologia. 2010 Jan;53(1):36-44. doi: 10.1007/s00125-009-1569-3. Epub 2009 Nov 7.

PMID:
19898832
[PubMed - indexed for MEDLINE]
14.

Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH.

Touraine P, D'Souza GA, Kourides I, Abs R, Barclay P, Xie R, Pico A, Torres-Vela E, Ekman B; GH Lipoatrophy Study Group.

Eur J Endocrinol. 2009 Oct;161(4):533-40. doi: 10.1530/EJE-09-0422. Epub 2009 Aug 4.

PMID:
19654233
[PubMed - indexed for MEDLINE]
Free Article
15.

Paroxysmal nonkinesigenic dyskinesias due to recurrent hypoglycemia caused by an insulinoma.

Debruyne F, Van Paesschen W, Van Eyken P, Bex M, Vandenberghe W.

Mov Disord. 2009 Feb 15;24(3):460-1. doi: 10.1002/mds.22386. No abstract available.

PMID:
19235926
[PubMed - indexed for MEDLINE]
16.

GNAS defects identified by stimulatory G protein alpha-subunit signalling studies in platelets.

Freson K, Izzi B, Labarque V, Van Helvoirt M, Thys C, Wittevrongel C, Bex M, Bouillon R, Godefroid N, Proesmans W, de Zegher F, Jaeken J, Van Geet C.

J Clin Endocrinol Metab. 2008 Dec;93(12):4851-9. doi: 10.1210/jc.2008-0883. Epub 2008 Sep 23.

PMID:
18812479
[PubMed - indexed for MEDLINE]
17.

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.

Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schöffski P.

Br J Cancer. 2008 Aug 5;99(3):448-54. doi: 10.1038/sj.bjc.6604497.

PMID:
18665181
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Divergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegaly.

Alexopoulou O, Bex M, Abs R, T'Sjoen G, Velkeniers B, Maiter D.

J Clin Endocrinol Metab. 2008 Apr;93(4):1324-30. doi: 10.1210/jc.2007-2104. Epub 2008 Jan 29.

PMID:
18230660
[PubMed - indexed for MEDLINE]
19.

Improved synthesis and metabolic stability analysis of the dopamine transporter ligand [(18)F]FECT.

Chitneni SK, Garreau L, Cleynhens B, Evens N, Bex M, Vermaelen P, Chalon S, Busson R, Guilloteau D, Van Laere K, Verbruggen A, Bormans G.

Nucl Med Biol. 2008 Jan;35(1):75-82. Epub 2007 Nov 19.

PMID:
18158946
[PubMed - indexed for MEDLINE]
20.

Is the management of thyroid nodules and differentiated thyroid cancer in accordance with recent consensus guidelines? - Results of a national survey.

Van den Bruel A, Moreno-Reyes R, Bex M, Daumerie C, Glinoer D.

Clin Endocrinol (Oxf). 2008 Apr;68(4):599-604. Epub 2007 Nov 6.

PMID:
17986280
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk